These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 38438322)
1. Plasma ctDNA Monitoring of a PTCH1-Mutant Metastatic Adult Medulloblastoma Showing a Durable Benefit With Vismodegib. Cabezas-Camarero S; García-Barberán V; Pérez-Alfayate R; Gómez Del Pulgar ME; Cabrera-Martin MN; Casado-Fariñas I; Pérez-Segura P Oncologist; 2024 May; 29(5):377-383. PubMed ID: 38438322 [TBL] [Abstract][Full Text] [Related]
2. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis. Li Y; Song Q; Day BW Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788 [TBL] [Abstract][Full Text] [Related]
3. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. Robinson GW; Orr BA; Wu G; Gururangan S; Lin T; Qaddoumi I; Packer RJ; Goldman S; Prados MD; Desjardins A; Chintagumpala M; Takebe N; Kaste SC; Rusch M; Allen SJ; Onar-Thomas A; Stewart CF; Fouladi M; Boyett JM; Gilbertson RJ; Curran T; Ellison DW; Gajjar A J Clin Oncol; 2015 Aug; 33(24):2646-54. PubMed ID: 26169613 [TBL] [Abstract][Full Text] [Related]
4. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Kool M; Jones DT; Jäger N; Northcott PA; Pugh TJ; Hovestadt V; Piro RM; Esparza LA; Markant SL; Remke M; Milde T; Bourdeaut F; Ryzhova M; Sturm D; Pfaff E; Stark S; Hutter S; Seker-Cin H; Johann P; Bender S; Schmidt C; Rausch T; Shih D; Reimand J; Sieber L; Wittmann A; Linke L; Witt H; Weber UD; Zapatka M; König R; Beroukhim R; Bergthold G; van Sluis P; Volckmann R; Koster J; Versteeg R; Schmidt S; Wolf S; Lawerenz C; Bartholomae CC; von Kalle C; Unterberg A; Herold-Mende C; Hofer S; Kulozik AE; von Deimling A; Scheurlen W; Felsberg J; Reifenberger G; Hasselblatt M; Crawford JR; Grant GA; Jabado N; Perry A; Cowdrey C; Croul S; Zadeh G; Korbel JO; Doz F; Delattre O; Bader GD; McCabe MG; Collins VP; Kieran MW; Cho YJ; Pomeroy SL; Witt O; Brors B; Taylor MD; Schüller U; Korshunov A; Eils R; Wechsler-Reya RJ; Lichter P; Pfister SM; Cancer Cell; 2014 Mar; 25(3):393-405. PubMed ID: 24651015 [TBL] [Abstract][Full Text] [Related]
5. Genetic ablation of Gpr37l1 delays tumor occurrence in Ptch1 Di Pietro C; La Sala G; Matteoni R; Marazziti D; Tocchini-Valentini GP Exp Neurol; 2019 Feb; 312():33-42. PubMed ID: 30452905 [TBL] [Abstract][Full Text] [Related]
6. Pik3ca mutations significantly enhance the growth of SHH medulloblastoma and lead to metastatic tumour growth in a novel mouse model. Niesen J; Ohli J; Sedlacik J; Dührsen L; Hellwig M; Spohn M; Holsten T; Schüller U Cancer Lett; 2020 May; 477():10-18. PubMed ID: 32112900 [TBL] [Abstract][Full Text] [Related]
7. Transcriptional repressor REST drives lineage stage-specific chromatin compaction at Dobson THW; Tao RH; Swaminathan J; Maegawa S; Shaik S; Bravo-Alegria J; Sharma A; Kennis B; Yang Y; Callegari K; Haltom AR; Taylor P; Kogiso M; Qi L; Khatua S; Goldman S; Lulla RR; Fangusaro J; MacDonald TJ; Li XN; Hawkins C; Rajaram V; Gopalakrishnan V Sci Signal; 2019 Jan; 12(565):. PubMed ID: 30670636 [TBL] [Abstract][Full Text] [Related]
8. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Pricl S; Cortelazzi B; Dal Col V; Marson D; Laurini E; Fermeglia M; Licitra L; Pilotti S; Bossi P; Perrone F Mol Oncol; 2015 Feb; 9(2):389-97. PubMed ID: 25306392 [TBL] [Abstract][Full Text] [Related]
9. Differences in RNA and microRNA Expression Between PTCH1- and SUFU-mutated Medulloblastoma. Gershanov S; Toledano H; Pernicone N; Fichman S; Michowiz S; Pinhasov A; Goldenberg-Cohen N; Listovsky T; Salmon-Divon M Cancer Genomics Proteomics; 2021; 18(3):335-347. PubMed ID: 33893086 [TBL] [Abstract][Full Text] [Related]
10. Lateral cerebellum is preferentially sensitive to high sonic hedgehog signaling and medulloblastoma formation. Tan IL; Wojcinski A; Rallapalli H; Lao Z; Sanghrajka RM; Stephen D; Volkova E; Korshunov A; Remke M; Taylor MD; Turnbull DH; Joyner AL Proc Natl Acad Sci U S A; 2018 Mar; 115(13):3392-3397. PubMed ID: 29531057 [TBL] [Abstract][Full Text] [Related]
11. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Gajjar A; Stewart CF; Ellison DW; Kaste S; Kun LE; Packer RJ; Goldman S; Chintagumpala M; Wallace D; Takebe N; Boyett JM; Gilbertson RJ; Curran T Clin Cancer Res; 2013 Nov; 19(22):6305-12. PubMed ID: 24077351 [TBL] [Abstract][Full Text] [Related]
12. MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation. Frappaz D; Barritault M; Montané L; Laigle-Donadey F; Chinot O; Le Rhun E; Bonneville-Levard A; Hottinger AF; Meyronnet D; Bidaux AS; Garin G; Pérol D Neuro Oncol; 2021 Nov; 23(11):1949-1960. PubMed ID: 33825892 [TBL] [Abstract][Full Text] [Related]
13. scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy. Ocasio JK; Babcock B; Malawsky D; Weir SJ; Loo L; Simon JM; Zylka MJ; Hwang D; Dismuke T; Sokolsky M; Rosen EP; Vibhakar R; Zhang J; Saulnier O; Vladoiu M; El-Hamamy I; Stein LD; Taylor MD; Smith KS; Northcott PA; Colaneri A; Wilhelmsen K; Gershon TR Nat Commun; 2019 Dec; 10(1):5829. PubMed ID: 31863004 [TBL] [Abstract][Full Text] [Related]
14. SHH inhibitors for the treatment of medulloblastoma. Samkari A; White J; Packer R Expert Rev Neurother; 2015; 15(7):763-70. PubMed ID: 26027634 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma. Rodriguez-Blanco J; Pednekar L; Penas C; Li B; Martin V; Long J; Lee E; Weiss WA; Rodriguez C; Mehrdad N; Nguyen DM; Ayad NG; Rai P; Capobianco AJ; Robbins DJ Oncogene; 2017 Nov; 36(45):6306-6314. PubMed ID: 28714964 [TBL] [Abstract][Full Text] [Related]
16. PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition. Metcalfe C; Alicke B; Crow A; Lamoureux M; Dijkgraaf GJ; Peale F; Gould SE; de Sauvage FJ Cancer Res; 2013 Dec; 73(23):7034-42. PubMed ID: 24154871 [TBL] [Abstract][Full Text] [Related]
17. Prolonged response to vismodegib in a patient with systemic medulloblastoma metastases. Climans SA; Macdonald DR; Sutherland DE; Mason WP BMJ Case Rep; 2020 Oct; 13(10):. PubMed ID: 33122230 [TBL] [Abstract][Full Text] [Related]
18. Intraventricular SHH inhibition proves efficient in SHH medulloblastoma mouse model and prevents systemic side effects. Kresbach C; Holst L; Schoof M; Leven T; Göbel C; Neyazi S; Tischendorf J; Loose C; Wrzeszcz A; Yorgan T; Rutkowski S; Schüller U Neuro Oncol; 2024 Apr; 26(4):609-622. PubMed ID: 37767814 [TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity. Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224 [TBL] [Abstract][Full Text] [Related]
20. Clinical and mutational profiles of adult medulloblastoma groups. Wong GC; Li KK; Wang WW; Liu AP; Huang QJ; Chan AK; Poon MF; Chung NY; Wong QH; Chen H; Chan DTM; Liu XZ; Mao Y; Zhang ZY; Shi ZF; Ng HK Acta Neuropathol Commun; 2020 Nov; 8(1):191. PubMed ID: 33172502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]